Abstract
MicroRNA 29b (miR-29b) replacement therapy is effective for suppressing fibrosis in a mouse model. However, to develop clinical applications for miRNA mimics, the side effects of nucleic acid drugs have to be addressed. In this study, we focused on miRNA mimics in order to develop therapies for idiopathic pulmonary fibrosis. We developed a single-stranded RNA, termed "miR-29b Psh-match," that has a unique structure to avoid problems associated with the therapeutic uses of miRNAs. A comparison of miR-29b Psh-match and double-stranded one, termed "miR-29b mimic" indicated that the single-stranded form was significantly effective towards fibrosis according to both in vivo and in vitro experiments. This novel form of miR-29b may become the foundation for developing an effective therapeutic drug for pulmonary fibrosis.
MeSH terms
-
Administration, Inhalation
-
Animals
-
Bleomycin / adverse effects*
-
Fibroblasts / metabolism
-
Hydroxyproline / analysis
-
Male
-
Mice
-
Mice, Inbred C57BL
-
MicroRNAs / therapeutic use*
-
NIH 3T3 Cells
-
Pulmonary Fibrosis / chemically induced
-
Pulmonary Fibrosis / drug therapy*
-
Signal Transduction
-
Toll-Like Receptors / metabolism
-
Transforming Growth Factor beta / pharmacology
Substances
-
MIRN29 microRNA, mouse
-
MicroRNAs
-
Toll-Like Receptors
-
Transforming Growth Factor beta
-
Bleomycin
-
Hydroxyproline
Grants and funding
This research was supported in part by Grants-in-Aid for Scientific Research (B: 26296088) and (C: 16K09376) and a Grant-in-Aid for Exploratory Research (15K15100) from Japan Society for the Promotion of Science (JSPS) and supported in part by Strategic Research Foundation Grant-aided Project for Private Universities from the Ministry of Education, Culture, Sports, Science and Technology of Japan.